Breast Cancer Overview

Breast cancer represents one of the most consequential cancers globally, accounting for approximately 2.3 million new cases annually worldwide and substantial mortality despite improving outcomes. The disease primarily affects women, with approximately 1 in 8 women developing breast cancer during their lifetime in many populations. While substantially less common, breast cancer also occurs in men, accounting for less than 1 percent of cases. The substantial burden of disease in women combined with progressive improvements in outcomes makes breast cancer a particularly important focus of clinical care, research, and public health efforts globally.

The biological diversity of breast cancer has emerged as one of the most important developments in oncology over recent decades. Rather than representing a single disease, breast cancer encompasses multiple distinct subtypes with substantially different characteristics, treatment approaches, and prognoses. Hormone receptor status (estrogen receptor and progesterone receptor), HER2 status, and various molecular features define the major subtypes. Hormone receptor positive cancers respond to hormonal therapies. HER2-positive cancers respond to HER2-targeted therapies. Triple-negative breast cancers (lacking these receptors) require different treatment approaches. The biological diversity has driven increasingly personalized treatment approaches with corresponding improvements in outcomes for many subtypes.

The substantial improvements in breast cancer outcomes over recent decades reflect multiple factors including widespread mammographic screening identifying cancers at earlier stages, refined surgical techniques including breast-conserving approaches, advanced radiation therapy, hormonal therapies for hormone receptor positive disease, HER2-targeted therapies for HER2-positive disease, immunotherapy for selected triple-negative cancers, and various other advances. Patients today face better outcomes than those diagnosed even a decade ago. The overall 5-year survival rate now exceeds 90 percent, with substantial variation by stage and subtype.

This article examines breast cancer comprehensively. It explains what the disease is, identifies risk factors and protective factors, discusses symptoms and screening, addresses diagnosis and the major subtypes, examines treatment approaches, and frames prevention and survivorship considerations.

For more on broader context, see Understanding Different Types of Cancer.

⸻

What Breast Cancer Is

Breast cancer develops when cells in breast tissue undergo genetic changes leading to uncontrolled growth. Most breast cancers originate from cells lining the milk ducts (ductal carcinomas). A smaller proportion originate from the milk-producing lobules (lobular carcinomas). Various other less common types exist.

Invasive vs Non-Invasive

Breast cancers are classified by invasion. Ductal carcinoma in situ (DCIS) is non-invasive cancer confined to the ducts, sometimes considered Stage 0 cancer. Invasive ductal carcinoma is the most common invasive breast cancer, accounting for approximately 70 to 80 percent of cases. Invasive lobular carcinoma accounts for approximately 10 to 15 percent of cases and can be more difficult to detect because of its growth pattern.

Major Molecular Subtypes

Breast cancer is increasingly classified by molecular features. Hormone receptor positive (estrogen receptor positive and/or progesterone receptor positive) accounts for approximately 70 to 75 percent of cases. HER2-positive accounts for approximately 15 to 20 percent of cases (with overlap with hormone receptor positive in some). Triple-negative breast cancer (negative for ER, PR, and HER2) accounts for approximately 10 to 15 percent of cases. The subtypes have substantially different treatment approaches and outcomes.

Inflammatory Breast Cancer

Inflammatory breast cancer is an aggressive form characterized by skin redness and warmth, skin thickening with peau d'orange (orange-peel) appearance, often diffuse rather than mass-forming, and aggressive behavior. The condition requires aggressive treatment.

Male Breast Cancer

Male breast cancer accounts for less than 1 percent of breast cancers. The cancer typically presents at older ages and may have specific characteristics. Treatment generally follows similar principles as female breast cancer.

For more on staging, see Cancer Staging Explained in Detail: TNM System, Clinical Significance, and Treatment Implications.

⸻

Risk Factors

Various factors affect breast cancer risk.

Age

Age is among the strongest risk factors. Risk increases substantially with age. Most cases occur in women over age 50.

Genetic Factors

Genetic factors contribute substantially. BRCA1 and BRCA2 mutations substantially increase risk. Lifetime breast cancer risk in BRCA1 mutation carriers approaches 70 percent. Lifetime breast cancer risk in BRCA2 mutation carriers approaches 65 percent. Other gene mutations including PALB2, ATM, CHEK2, and various others contribute to elevated risk.

Family History

Family history of breast cancer (particularly first-degree relatives, multiple affected relatives, or affected relatives at younger ages) increases risk.

Personal History

Personal history affects risk including previous breast cancer, previous biopsy showing certain benign changes, previous chest radiation (particularly at young ages), and various others.

Reproductive Factors

Reproductive factors affect risk including early menarche (before age 12), late menopause (after age 55), never having children or having children at older ages, not breastfeeding, and various others. The factors affect lifetime estrogen exposure.

Hormonal Factors

Hormonal factors affect risk including hormone replacement therapy (HRT), particularly combined estrogen and progestin, and various others.

Lifestyle Factors

Various lifestyle factors affect risk including excessive alcohol consumption, obesity (particularly after menopause), sedentary lifestyle, and various others.

Breast Density

High breast density on mammography is associated with elevated risk. Dense breasts can also affect screening sensitivity.

For more on prevention, see Cancer Risk Factors and Prevention: Understanding What Increases Risk and How to Reduce It.

⸻

Symptoms

Breast cancer symptoms vary and can be subtle, particularly in early stages.

Often Asymptomatic Early

Many early breast cancers are detected through screening rather than symptoms. Mammographic detection often identifies cancers before they produce symptoms.

Common Symptoms

Common symptoms include breast lump or thickening, change in breast size or shape, skin changes including dimpling, puckering, or redness, nipple changes including inversion, scaling, or discharge, bloody nipple discharge particularly, breast pain (less commonly), lymph node enlargement in the armpit, and various others.

Inflammatory Breast Cancer Symptoms

Inflammatory breast cancer produces specific symptoms: rapidly developing redness, warmth, and swelling, skin thickening with peau d'orange appearance, often without a discrete lump. The symptoms can be confused with infection. Persistent or progressive symptoms warrant evaluation.

For more on early signs of cancer, see Early Signs and Symptoms of Cancer: What to Watch For and When to Seek Medical Evaluation.

For more details on breast symptoms, see Breast Cancer Symptoms and Early Warning Signs.

⸻

Screening

Screening identifies breast cancers at earlier stages.

Mammography

Mammography is the primary screening method. The technique uses X-ray imaging to identify abnormalities. Modern digital mammography and 3D mammography (tomosynthesis) provide improved detection.

Recommendations

Recommendations vary somewhat among organizations. Generally screening starts at age 40 to 50. Annual or biennial screening is typical. Continuation generally through age 75, with individualized decisions through older ages. Earlier or more frequent screening for higher-risk individuals.

Risk-Based Adjustments

Various risk factors affect screening including family history, genetic mutations, previous chest radiation, and various others. High-risk individuals may benefit from MRI screening in addition to mammography.

Limitations

Limitations include false positives requiring follow-up, some false negatives, limited sensitivity in dense breasts, and various others. The benefits generally exceed the risks for appropriate screening.

For more on related considerations, see Cancer Staging Explained in Detail: TNM System, Clinical Significance, and Treatment Implications.

⸻

Diagnosis

The diagnostic process for breast cancer typically involves several elements.

Imaging

Imaging beyond initial mammography may include diagnostic mammography for suspicious findings, ultrasound for evaluation of palpable findings or specific abnormalities, MRI for selected situations including evaluation of high-risk patients, dense breasts, or specific findings, and various others.

Biopsy

Biopsy provides definitive diagnosis. Various biopsy approaches include core needle biopsy (typically the first approach), vacuum-assisted biopsy for some situations, surgical biopsy when needed, and various others.

Pathology

Pathologic evaluation provides specific cancer type, histologic grade, hormone receptor status (estrogen receptor and progesterone receptor), HER2 status, various molecular features, and various others.

Molecular Testing

Molecular testing increasingly guides treatment including hormone receptors, HER2 status, BRCA1 and BRCA2 testing for selected patients, multigene panels for prognosis (such as Oncotype DX, MammaPrint, and various others), and various other markers including PD-L1 for selected patients.

For more on diagnosis, see How Cancer Is Diagnosed: From Initial Symptoms to Biopsy and Molecular Testing.

⸻

Major Molecular Subtypes

Different molecular subtypes have different characteristics and treatments.

Hormone Receptor Positive

Hormone receptor positive cancers express estrogen receptor and/or progesterone receptor. They account for approximately 70 to 75 percent of breast cancers, generally respond to hormonal therapies, often have somewhat better prognoses than other subtypes, and carry a risk of recurrence that can persist for many years (sometimes decades). Treatment includes hormonal therapy along with various other approaches.

HER2-Positive

HER2-positive cancers overexpress HER2 protein. They account for approximately 15 to 20 percent of cases, were historically more aggressive than other subtypes before targeted therapy, and now have substantially improved outcomes with HER2-targeted therapies. Treatment includes trastuzumab, pertuzumab, ado-trastuzumab emtansine, trastuzumab deruxtecan, and various others.

Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) lacks ER, PR, and HER2 expression. It accounts for approximately 10 to 15 percent of cases, is generally more aggressive than other subtypes, and is often more common in younger women, African American women, and BRCA1 mutation carriers. Treatment now includes immunotherapy for selected patients.

For more on related concepts, see Most Commonly Misdiagnosed Conditions.

⸻

Treatment

Treatment varies substantially by stage and molecular subtype.

Surgery

Surgery is central to most breast cancer treatment. Options include lumpectomy (breast-conserving surgery) removing the tumor with margins of normal tissue (often combined with radiation therapy), mastectomy removing the entire breast (various types include simple, modified radical, and various others), sentinel lymph node biopsy or axillary lymph node dissection to evaluate lymph nodes, and reconstruction available for many patients undergoing mastectomy.

Radiation Therapy

Radiation therapy is often used after lumpectomy to treat the remaining breast tissue, after mastectomy in some situations, for locally advanced disease, for metastatic disease in some situations, and various other situations. Modern radiation approaches reduce side effects compared to older techniques.

Chemotherapy

Chemotherapy is used in the adjuvant setting after surgery, in the neoadjuvant setting before surgery, and for metastatic disease. Various combinations are used depending on specific situation.

Hormonal Therapy

Hormonal therapy is used for hormone receptor positive cancers including tamoxifen, aromatase inhibitors (anastrozole, letrozole, exemestane), ovarian suppression in selected premenopausal women, and various others. Treatment is typically continued for 5 to 10 years or longer.

HER2-Targeted Therapy

HER2-targeted therapy is used for HER2-positive cancers including trastuzumab (Herceptin), pertuzumab, ado-trastuzumab emtansine, trastuzumab deruxtecan, and various others. The therapies have substantially transformed HER2-positive breast cancer outcomes.

CDK4/6 Inhibitors

CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are used for hormone receptor positive metastatic breast cancer in combination with hormonal therapies.

PARP Inhibitors

PARP inhibitors (olaparib, talazoparib) are used for selected patients with BRCA mutations.

Immunotherapy

Immunotherapy is used for triple-negative breast cancer with PD-L1 expression in some situations.

For more on side effects, see Side Effects of Cancer Treatments.

For more on consultation, see When Should You See an Oncologist? Early Warning Signs Explained.

⸻

Staging

Staging determines extent of disease.

TNM System

The TNM system stages breast cancer: T (tumor size and characteristics), N (lymph node involvement), M (distant metastasis).

Survival by Stage

5-year survival varies substantially. Stage 0 (DCIS): approaching 100 percent. Stage I: approximately 99 percent. Stage II: approximately 86 percent. Stage III: approximately 65 to 80 percent depending on substage. Stage IV: approximately 30 percent overall, with substantial variation by subtype and improving with modern therapies.

For more details, see Cancer Staging Explained in Detail: TNM System, Clinical Significance, and Treatment Implications.

⸻

Genetic Testing

Genetic testing identifies hereditary breast cancer.

Indications for Testing

Indications include family history meeting specific criteria, personal history of breast cancer at younger ages, multiple cancers (breast plus ovarian, for example), triple-negative breast cancer, male breast cancer, and various others.

Implications of Positive Results

Positive results affect treatment decisions for the affected patient, risk-reducing recommendations, family member implications, and surveillance recommendations.

Genetic Counseling

Genetic counseling supports informed decisions about testing and managing results.

⸻

Prevention

Various approaches contribute to breast cancer prevention.

Lifestyle Modifications

Various lifestyle modifications may reduce risk including maintaining healthy weight, regular physical activity, limited alcohol consumption, breastfeeding when applicable, and various others.

Risk-Reducing Medications

For high-risk women, risk-reducing medications may be considered including tamoxifen, aromatase inhibitors, and various others. The decisions involve risk-benefit considerations.

Risk-Reducing Surgery

For very high-risk women (such as BRCA mutation carriers), risk-reducing mastectomy may be considered.

For more on related considerations, see Cancer Risk Factors and Prevention: Understanding What Increases Risk and How to Reduce It.

⸻

Survivorship

Patients treated for breast cancer require ongoing care.

Surveillance

Surveillance includes periodic clinical visits, annual mammography, MRI for selected high-risk patients, and various others.

Management of Treatment Effects

Management of treatment effects includes lymphedema management, sexual function and intimacy, bone health (particularly with aromatase inhibitors), cardiovascular monitoring, cognitive effects, mental health support, and various others.

Risk of Recurrence

Risk of recurrence varies by initial stage and subtype. Hormone receptor positive cancers can recur many years after initial treatment.

⸻

Common Misconceptions

Several misconceptions about breast cancer deserve attention.

• Only women get breast cancer — Breast cancer occurs in men, accounting for less than 1 percent of cases.
• Breast cancer always causes a lump — Various symptoms can occur. Some cancers (particularly inflammatory) may not have a discrete lump.
• Family history is required for risk — Most breast cancers occur in patients without family history.
• All breast cancers are treated the same — Treatment varies substantially by molecular subtype and stage.
• Mastectomy is always required — Many patients are candidates for breast-conserving surgery.
• Hormone receptor positive cancers don't recur — Hormone receptor positive cancers can recur many years after initial treatment.

⸻

Special Patient Populations

Several specific populations have particular considerations.

Young Women

Young women with breast cancer face specific considerations including fertility, life-stage implications, and often distinct biology.

Older Women

Older women face considerations regarding comorbidities and treatment tolerance.

Pregnant Patients

Pregnancy presents complex situations balancing maternal and fetal considerations.

Men With Breast Cancer

Men with breast cancer face often-delayed diagnosis and various considerations.

Patients With BRCA Mutations

Patients with BRCA mutations face specific risk patterns and treatment implications.

⸻

When to See a Specialist

Various specialists are involved in breast cancer care. Primary care physicians often initiate evaluation. Breast surgeons or surgical oncologists perform surgery. Medical oncologists manage chemotherapy, hormonal therapy, targeted therapy, and immunotherapy. Radiation oncologists manage radiation therapy. Pathologists provide tissue diagnosis. Plastic surgeons perform reconstruction. Genetic counselors evaluate hereditary cancer concerns. For complex situations, evaluation at major cancer centers provides specialized expertise.

⸻

Conclusion

Breast cancer is one of the most common cancers globally, with approximately 2.3 million new cases annually. The disease primarily affects women (1 in 8 lifetime risk in many populations) but also occurs in men. Substantial improvements in outcomes over recent decades reflect screening, refined treatments, and increasingly personalized approaches.

Breast cancer originates from cells in breast tissue. Most cases are ductal carcinomas; lobular carcinomas account for 10 to 15 percent. DCIS represents non-invasive disease. Major molecular subtypes include hormone receptor positive (70 to 75 percent), HER2-positive (15 to 20 percent), and triple-negative (10 to 15 percent), each with distinct treatment approaches. Inflammatory breast cancer is an aggressive form. Male breast cancer accounts for less than 1 percent.

Risk factors include age, female sex, genetic factors (BRCA1/2, PALB2, ATM, CHEK2, various others), family history, personal history, reproductive factors, hormonal factors (HRT), lifestyle factors (alcohol, obesity, sedentary lifestyle), high breast density, and various others.

Symptoms include breast lump or thickening, size or shape changes, skin changes (dimpling, redness), nipple changes, bloody discharge, breast pain (less commonly), lymph node enlargement, and various others. Many early cancers are asymptomatic and detected by screening. Inflammatory breast cancer produces specific skin changes.

Screening with mammography (digital and 3D) is the primary approach. Recommendations generally include screening starting at age 40 to 50, with adjustments for risk factors. High-risk individuals may benefit from MRI screening.

Diagnosis involves imaging, biopsy (typically core needle), pathology including hormone receptor and HER2 status, molecular testing including BRCA testing and multigene prognostic panels, and staging workup.

Treatment includes surgery (lumpectomy or mastectomy with reconstruction options, sentinel node biopsy or axillary dissection), radiation therapy, chemotherapy (adjuvant, neoadjuvant, or metastatic), hormonal therapy (tamoxifen, aromatase inhibitors, ovarian suppression), HER2-targeted therapy (trastuzumab, pertuzumab, ado-trastuzumab emtansine, trastuzumab deruxtecan), CDK4/6 inhibitors, PARP inhibitors for BRCA mutations, and immunotherapy for selected triple-negative cancers.

Staging using TNM produces stages 0 through IV. 5-year survival ranges from approaching 100 percent for Stage 0 to approximately 30 percent for Stage IV with substantial improvement with modern therapies.

The encouraging element is that breast cancer outcomes have improved substantially with screening, refined treatments, and increasingly personalized approaches.

⸻

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Individuals should consult a qualified healthcare provider for diagnosis and treatment.